Real-world Perspectives on Novel HER2-Targeted and TROP-2–Directed Therapies in Advanced Breast Cancer
Discussion between experts on novel and emerging HER2-targeted and TROP-2–directed therapies for patients with HER2-low, hormone receptor–positive, and triple-negative advanced breast cancer.
Decera Clinical Education Oncology Podcast · Sara M. Tolaney MD MPH, Melinda Telli MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this podcast episode, Sara M. Tolaney, MD, MPH, and Melinda Telli, MD, delve into the critical aspects of the current therapeutic landscape for patients with unresectable or metastatic HER2-low, hormone receptor–positive, and triple-negative breast cancer, including:
- Challenges with the pathologic testing for HER2-low expression
- Optimal treatment of patients with HER2-low advanced breast cancer
- Role of TROP-2–targeted therapies
- Management of ADC-associated adverse events to optimize treatment outcomes
- ADCs on the horizon for patients with advanced breast cancer
Presenters:
Sara M. Tolaney, MD, MPH
Chief, Division of Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Melinda Telli, MD
Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California
Content based on an online CME program supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.
Link to full program:
https://bit.ly/49WxRBM
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.